Inhibikase Therapeutics Inc (IKT) Stock Price, Quote & News

Company Profile

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia....

Industry: Biotechnology

Sector: Healthcare

Phone: (678) 392-3419

Website: www.inhibikase.com

Address:

3350 Riverwood Parkway SE, Suite 1900, Atlanta, United States

BillyTheKid62 Sep. 12 at 8:26 PM

$IKT This stock has died i think!

0 · Reply

BillyTheKid62 Sep. 5 at 4:41 PM

$IKT I wish I was a CEO of a publicly traded Bio company . If nothing ever happens with the company let the retail shareholders hemmroids bleed out .

0 · Reply

MB11111 Sep. 4 at 2:14 PM

$IKT with such a long runway before any news, this will sink into the abyss.

0 · Reply

BillyTheKid62 Aug. 30 at 7:03 PM

$IKT This stock is a bigger pain in my ass than my bleeding hemmroids .

1 · Reply

MB11111 Aug. 29 at 3:25 PM

$IKT news on LinkedIn….first in 8 months work has started!…a Power Point présentation!! 😃 https://www.linkedin.com/posts/inhibikase-therapeutics_corporate-ikt-investor-deck-activity-7367204376806969344-8TAl?utm_medium=ios_app&rcm=ACoAAAr-G-oBWKvt9DTkJFDOF6dtn33MksfZCq0&utm_source=social_share_send&utm_campaign=copy_link

2 · Reply

TJC1791 Aug. 27 at 8:56 PM

$IKT in case anyone cares about what Milton is up to these days.

1 · Reply

PercentGainz Aug. 27 at 9:41 AM

$IKT building a base, watching for breakout confirmation.

0 · Reply

SophieAllan6 Aug. 25 at 3:07 PM

$IKT Let's keep an eye on that price target together!

0 · Reply

StockScanners Aug. 23 at 5:47 PM

$IKT keep watch if this holds above 1.73

0 · Reply

TJC1791 Aug. 19 at 9:06 PM

$IKT https://www.inhibikase.com/news/press-releases/detail/133/inhibikase-therapeutics-strengthens-leadership-team-with

3 · Reply

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

Aug 14, 2025, 4:50 PM EDT - 4 weeks ago

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

May 14, 2025, 4:05 PM EDT - 4 months ago

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

Apr 14, 2025, 8:00 AM EDT - 5 months ago

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Mar 27, 2025, 4:01 PM EDT - 6 months ago

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Feb 24, 2025, 8:00 AM EST - 7 months ago

Inhibikase Announces Expansion of Senior Leadership Team

Feb 18, 2025, 8:00 AM EST - 7 months ago

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

Jan 29, 2025, 6:30 PM EST - 8 months ago

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study

Nov 19, 2024, 1:32 PM EST - 10 months ago

Inhibikase: Potential To Improve Current Treatment Options For PAH Patients

Nov 14, 2024, 8:37 AM EST - 10 months ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Oct 21, 2024, 9:05 AM EDT - 11 months ago

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Oct 9, 2024, 9:18 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Aug 15, 2024, 6:13 PM EDT - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:25 PM EDT - 1 year ago

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Jun 17, 2024, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Jun 5, 2024, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

May 20, 2024, 8:01 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

May 17, 2024, 9:57 PM EDT - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript

May 15, 2024, 8:00 PM EDT - 1 year ago

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

May 15, 2024, 8:45 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

May 9, 2024, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Apr 18, 2024, 4:30 PM EDT - 1 year ago

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Apr 3, 2024, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Mar 28, 2024, 5:13 PM EDT - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 4:15 PM EDT - 1 year ago

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Mar 7, 2024, 8:30 AM EST - 1 year ago

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Feb 28, 2024, 4:05 PM EST - 1 year ago

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Feb 7, 2024, 7:55 AM EST - 1 year ago

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

Jan 29, 2024, 9:05 AM EST - 1 year ago

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Jan 16, 2024, 4:05 PM EST - 1 year ago

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Dec 4, 2023, 8:35 AM EST - 1 year ago

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Nov 15, 2023, 5:38 PM EST - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript

Nov 14, 2023, 4:30 PM EST - 1 year ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Nov 7, 2023, 9:28 AM EST - 2 years ago

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

Oct 16, 2023, 7:00 AM EDT - 2 years ago

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

Oct 4, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

Aug 24, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Aug 21, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Aug 17, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

Aug 7, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

Jul 17, 2023, 4:05 PM EDT - 2 years ago

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jun 29, 2023, 9:29 AM EDT - 2 years ago

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

Jun 22, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Jun 21, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease

May 30, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Present at the LD Micro Invitational XIII

May 16, 2023, 9:38 AM EDT - 2 years ago

Inhibikase Therapeutics, Inc. (IKT) Q1 2023 Earnings Call Transcript

May 16, 2023, 7:45 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease

BillyTheKid62 Sep. 12 at 8:26 PM

$IKT This stock has died i think!

0 · Reply

BillyTheKid62 Sep. 5 at 4:41 PM

$IKT I wish I was a CEO of a publicly traded Bio company . If nothing ever happens with the company let the retail shareholders hemmroids bleed out .

0 · Reply

MB11111 Sep. 4 at 2:14 PM

$IKT with such a long runway before any news, this will sink into the abyss.

0 · Reply

BillyTheKid62 Aug. 30 at 7:03 PM

$IKT This stock is a bigger pain in my ass than my bleeding hemmroids .

1 · Reply

MB11111 Aug. 29 at 3:25 PM

2 · Reply

TJC1791 Aug. 27 at 8:56 PM

$IKT in case anyone cares about what Milton is up to these days.

1 · Reply

PercentGainz Aug. 27 at 9:41 AM

$IKT building a base, watching for breakout confirmation.

0 · Reply

SophieAllan6 Aug. 25 at 3:07 PM

$IKT Let's keep an eye on that price target together!

0 · Reply

StockScanners Aug. 23 at 5:47 PM

$IKT keep watch if this holds above 1.73

0 · Reply

TJC1791 Aug. 19 at 9:06 PM

$IKT https://www.inhibikase.com/news/press-releases/detail/133/inhibikase-therapeutics-strengthens-leadership-team-with

3 · Reply

d_risk Aug. 17 at 5:23 AM

$IKT - Inhibikase Therapeutics, Inc. - 10Q - Updated Risk Factors IKT flags new risks from potential healthcare cost-cutting laws and U.S. tax changes, plus updates on trade uncertainty and tariffs impacting raw materials despite pharma product exemptions. #Biotechnology #Pharmaceuticals #TradeUncertainty #TaxRisk #HealthcareCosts 🟢 Added 🟠 Removed https://d-risk.ai/IKT/10-Q/2025-08-14

1 · Reply

TJC1791 Aug. 14 at 8:54 PM

$IKT https://www.inhibikase.com/news/press-releases/detail/132/inhibikase-therapeutics-announces-second-quarter2025 PAH trial will start in the “back half”.

0 · Reply

thelingletingle Aug. 14 at 2:10 PM

$IKT Has this company been abducted by ICE?

1 · Reply

Mjf04288 Aug. 13 at 2:07 PM

$IKT Earnings today?

1 · Reply

RnJhc2Vy Aug. 9 at 5:04 AM

$IKT This drop is concerning.

0 · Reply

buffalochips62 Aug. 8 at 4:17 PM

$IKT I have never seen such a inactive, Stocktwits page. It’s weird. OK well if anyone is listening, are you expecting to hear updates on any catalyst at the ER next week?

2 · Reply

Fib7867 Aug. 7 at 3:15 AM

#myIKTanalysis $IKT

0 · Reply

BillyTheKid62 Aug. 1 at 5:40 PM

$IKT This stock makes my hemmroids bleed faster !

1 · Reply

buffalochips62 Jul. 31 at 3:10 PM

$IKT seems this is just gonna keep slowly bleeding back to 1. Ugh.

2 · Reply

MB11111 Jul. 24 at 2:38 PM

$IKT Ikt is hiring. Clinical trial jobs… https://www.inhibikase.com/careers Careers :: Inhibikase Therapeutics, Inc. (IKT)

1 · Reply

buffalochips62 Jul. 24 at 1:51 PM

$IKT is the feed to this ticker broken or is it just me? I don’t see any updates in 12 days.?

0 · Reply

Mjf04288 Jul. 11 at 3:45 PM

$IKT Volume has dried up the past 2 days. Company needs to provide some updates

1 · Reply

Market Cap	116.25M
Revenue (ttm)	0.00
Net Income (ttm)	-27.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	78,600
Avg Vol	110,212
Day's Range	N/A - N/A
Shares Out	74.52M
Stochastic %K	18%
Beta	0.92
Analysts	Strong Sell
Price Target	$8.00